Evidence map›Paper›PMID 35519159›Full record

ArticleThe Pan African medical journal2022

[HemoTypeSC screening for sickle cell disease in the Democratic Republic of Congo (DRC): a case from the city of Kindu].

Abdala Kingwengwe Aimé, Shindano Mwamba Etienne, Destin Mbongi, Didier Nsonso, Erik Serrao, Tshilolo Muepu Malaika Léon, Luboya Numbi Oscar, Wembonyama Okitotsho Stanis

Abstract read
In one paragraph

Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Epidemiologic profile of hemoglobinopathies in Benin.Hematology, transfusion and cell therapy · 2024
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdala Kingwengwe AiméDépartement de Pédiatrie, Faculté de Médecine, Université de Kindu, Kindu, République Démocratique du Congo.
Shindano Mwamba EtienneDépartement de Pédiatrie, Faculté de Médecine, Université de Kindu, Kindu, République Démocratique du Congo.
Destin MbongiCentre Hospitalier Mère-Enfant de Monkole, Kinshasa, République Démocratique du Congo.
Didier NsonsoCentre Hospitalier Mère-Enfant de Monkole, Kinshasa, République Démocratique du Congo.
Erik SerraoSilver Lake Research Corporation, Azusa, California, United States of America.
Tshilolo Muepu Malaika LéonCentre Hospitalier Mère-Enfant de Monkole, Kinshasa, République Démocratique du Congo.
Luboya Numbi OscarDépartement de Pédiatrie, Faculté de Médecine, Université de Lubumbashi, Lubumbashi, République Démocratique du Congo.
Wembonyama Okitotsho StanisDépartement de Pédiatrie, Faculté de Médecine, Université de Lubumbashi, Lubumbashi, République Démocratique du Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of sickle cell disease is crucial to improve people's survival. Both financial and geographic accessibility to sickle cell disease tools are barriers to universal screening in developing countries. The purpose of this study was to determine the hospital prevalence of sickle cell disease and to assess the reliability of a rapid diagnostic tool, HemoTypeSC, in a resource-limited environment. We conducted a prospective cross-sectional descriptive study in the Department of Pediatrics of 5 health facilities in the city of Kindu, Maniema province, DRC, over a period of 10 months. The study consisted of HemoType SC rapid test screening for sickle cell disease and then diagnostic confirmation by hemoglobin electrophoresis. A total of 448 children less than 5 years of age were enrolled in the study. The overall hospital prevalence of patients with sickle cell disease was 31.9%, of whom 12.7% were homozygous (SS) and 19.2% trait carriers; the level of suspicion for sickle cell disease in hospitals was 6%; the clinical presumption regarding sickle cell disease was 8%; HemoType SC rapid test had good indicators of validity for the detection of hemoglobins A and S. The study shows that the hospital prevalence of major sickle cell disease is higher in children under 5 years of age with respect to clinical suspicion in the absence of laboratory tests. HemoTypeSC rapid test seems to be a reliable tool for the screening of the disease in the city of Kindu, a resource-limited environment.

Indexed as

Anemia, Sickle CellChildChild, PreschoolCross-Sectional StudiesDemocratic Republic of the CongoHumansProspective StudiesReproducibility of ResultschildDemocratic Republic of CongodiagnosticHemoTypeSChospital screeningKindurapid testSickle cell disease

Identifiers

PMID35519159
PMCPMC9034557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.